Continuation of a randomized, double-blind, multicenter study of linezolid versus vancomycin in the treatment of patients with nosocomial pneumonia.
about
Community acquired bacterial pneumoniaGuidelines for the Management of Adults with Hospital-acquired, Ventilator-associated, and Healthcare-associated PneumoniaGood clinical outcomes but high rates of adverse reactions during linezolid therapy for serious infections: a proposed protocol for monitoring therapy in complex patients.Methicillin-resistant Staphylococcus aureus nosocomial pneumonia: role of linezolid in the People's Republic of ChinaAntibiotics for ventilator-associated pneumonia.Novel pandemic influenza A (H1N1) and community-associated methicillin-resistant Staphylococcus aureus pneumonia.Linezolid does not increase the risk of thrombocytopenia in patients with nosocomial pneumonia: comparative analysis of linezolid and vancomycin use.A review of linezolid: the first oxazolidinone antibiotic.Efficacy and safety of linezolid in liver transplant patients.Treatment of hospital-acquired pneumonia with linezolid or vancomycin: a systematic review and meta-analysis.Higher clinical success in patients with ventilator-associated pneumonia due to methicillin-resistant Staphylococcus aureus treated with linezolid compared with vancomycin: results from the IMPACT-HAP studyLinezolid versus vancomycin for the treatment of suspected methicillin-resistant Staphylococcus aureus nosocomial pneumonia: a systematic review employing meta-analysis.Population pharmacokinetics and pharmacodynamics of linezolid-induced thrombocytopenia in hospitalized patients.Vancomycin-associated nephrotoxicity: grave concern or death by character assassination?Year in review 2012: Critical Care--respiratory infectionsWaves of resistance: Staphylococcus aureus in the antibiotic era.Clinical practice guidelines by the infectious diseases society of america for the treatment of methicillin-resistant Staphylococcus aureus infections in adults and children.Recommendations for improving the design, conduct, and analysis of clinical trials in hospital-acquired pneumonia and ventilator-associated pneumonia.Staphylococcus aureus infections: epidemiology, pathophysiology, clinical manifestations, and management.Efficacy and safety of linezolid compared with vancomycin in a randomized, double-blind study of febrile neutropenic patients with cancer.The efficacy and safety of linezolid and glycopeptides in the treatment of Staphylococcus aureus infectionsPharmacoeconomics of linezolid.Linezolid for the treatment of drug-resistant infections.Complicated skin and skin-structure infections and catheter-related bloodstream infections: noninferiority of linezolid in a phase 3 study.Linezolid vs glycopeptide antibiotics for the treatment of suspected methicillin-resistant Staphylococcus aureus nosocomial pneumonia: a meta-analysis of randomized controlled trials.LEADER Program results for 2009: an activity and spectrum analysis of linezolid using 6,414 clinical isolates from 56 medical centers in the United States.Antibiotic management of methicillin-resistant Staphylococcus aureus--associated acute pulmonary exacerbations in cystic fibrosis.The safety and efficacy of linezolid in orthopaedic practice for the treatment of infection due to antibiotic-resistant organisms.Vancomycin and the Risk of AKI: A Systematic Review and Meta-Analysis.Update on linezolid: the first oxazolidinone antibiotic.Guidelines for the prophylaxis and treatment of methicillin-resistant Staphylococcus aureus (MRSA) infections in the UK.Potential impact of vancomycin pulmonary distribution on treatment outcomes in patients with methicillin-resistant Staphylococcus aureus pneumonia.Community-associated meticillin-resistant Staphylococcus aureusVentilator-associated pneumonia: a review.Linezolid surveillance results for the United States: LEADER surveillance program 2011.Emerging options for treatment of invasive, multidrug-resistant Staphylococcus aureus infections.Pharmacologic treatment options for nosocomial pneumonia involving methicillin-resistant Staphylococcus aureus.Combating the growing problem of methicillin-resistant Staphylococcus aureus: do the newer antibiotics represent a better alternative to vancomycin?Vancomycin for treatment of invasive, multi-drug resistant Staphylococcus aureus infections.Multicenter evaluation of vancomycin dosing: emphasis on obesity.
P2860
Q22241379-5AA85636-7CC7-4250-BB86-6D971C35A22FQ22241905-DBA04F37-7B26-41B2-9101-8E0832736095Q24542412-842F4FF0-ECD6-4A16-A80B-7299417AEC5EQ26749179-56B5C8E3-EFD4-4657-940D-93A963141B98Q30243877-B90CFC1D-81BC-45A6-942C-14D274891C54Q30370676-70BBF4D5-759A-4A1C-B77D-618B60422F45Q33358278-A54A335D-E5B1-4047-BA5D-1057A05F1D33Q33363226-7328D82F-D735-4152-BE21-AE997C5CFF24Q33394330-74A94D48-C99E-47D9-969D-8227ADF2164AQ33410942-317A9DDD-29B1-4CD6-A0CD-C1D416751831Q33415857-10CDFC34-52DE-4A25-BB73-E0CBC04FEC43Q33418451-A560388B-960A-4658-B689-36E4094D5C64Q33439246-4B9A76B3-EEFA-44B5-A3E9-DC6C4E01E280Q33617737-D642C738-03C1-49D9-85FF-F1A083EDEABAQ33753788-314B5B10-1449-437B-9185-110815B5807CQ33854398-2E4895FD-79A2-4AE8-9A56-A6859123A317Q34157657-11E171DA-7124-42DE-A854-B254108A15C6Q34470298-B6A65EC9-925B-42E1-9EA9-4136CE577818Q34478074-DD339402-8FE6-4BCD-9212-914AA6141CD5Q34489730-B55A1EA7-4F51-4561-A0E9-B46608B5E95DQ34618696-03931AD4-1314-46D1-8EA0-382FF174DC8BQ34765976-5D6B1E28-EDED-462F-BAA9-91EAE7496121Q34894133-395EF2A9-CE53-47E3-A101-3D2F81B3FCB5Q34900607-2F15FDFA-E11A-4A8C-9C10-D86C270ECD90Q34923394-906E3246-B78E-4586-AFC4-E7EBC2A3D955Q35139437-018134A4-292B-4303-BED5-B9A09F50F7E5Q35542062-736402B0-78C9-4E4E-8A27-9BF6375BDFC4Q35873712-CA2DE47E-7E60-48A7-8120-BDF024C26821Q36206165-1721F8E0-7339-45D2-9B30-FB6A020C06BBQ36283744-C04D1B62-F5BF-4CB2-B06B-532FF4ED8FDAQ36409465-EB7D3E1B-A4A3-4A6A-A926-EDBBB8FB0AFEQ36428418-C077BF2B-944D-44CA-91D7-A2809E757814Q36438720-4A1BB7C3-DDC2-431D-BD12-B057DF4F1824Q36541263-1D64B71E-9216-4097-A43B-9626BA9F9C2FQ36558466-336CEB70-D7D9-43FC-B5C5-2CD19615BD52Q36718474-56E3417D-9BAA-4A99-A1B9-ED2996C3EAEBQ36735202-8AC8771E-18F9-489E-9A84-B9316EC20B68Q36839693-BDEE9D83-6EB2-4164-B0D6-FC715A0B6D59Q36847287-8F5F6781-D8C2-426B-95BF-7733EC8F876DQ36961341-4E5C66AF-F1C3-4621-A0B8-E2BC8CB41080
P2860
Continuation of a randomized, double-blind, multicenter study of linezolid versus vancomycin in the treatment of patients with nosocomial pneumonia.
description
2003 nî lūn-bûn
@nan
2003年の論文
@ja
2003年学术文章
@wuu
2003年学术文章
@zh
2003年学术文章
@zh-cn
2003年学术文章
@zh-hans
2003年学术文章
@zh-my
2003年学术文章
@zh-sg
2003年學術文章
@yue
2003年學術文章
@zh-hant
name
Continuation of a randomized, ...... nts with nosocomial pneumonia.
@en
Continuation of a randomized, ...... nts with nosocomial pneumonia.
@nl
type
label
Continuation of a randomized, ...... nts with nosocomial pneumonia.
@en
Continuation of a randomized, ...... nts with nosocomial pneumonia.
@nl
prefLabel
Continuation of a randomized, ...... nts with nosocomial pneumonia.
@en
Continuation of a randomized, ...... nts with nosocomial pneumonia.
@nl
P50
P1476
Continuation of a randomized, ...... nts with nosocomial pneumonia.
@en
P2093
Linezolid Nosocomial Pneumonia Study Group
Thomas H Oliphant
P304
P356
10.1016/S0149-2918(03)80118-2
P577
2003-03-01T00:00:00Z